Refine by
Chronic Kidney Disease Articles & Analysis
39 news found
“Despite progress in risk reduction in type 2 diabetes, chronic kidney disease in type 1 diabetes remains understudied, leaving a huge unmet need to reduce the risks of end-stage kidney disease and cardiovascular events. ...
ByBayer AG
In the prospective observational XARENO study, after a two year follow up period, Xarelto was associated with a reduced risk of adverse kidney outcomes and all-cause mortality in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD), compared to vitamin K antagonists (VKA) XARENO ...
ByBayer AG
Kerendia is now indicated for the treatment of chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults. ...
ByBayer AG
About Chronic Kidney Disease in Type 2 Diabetes Chronic kidney disease (CKD) is a common and potentially deadly condition that is widely underrecognized. ...
ByBayer AG
About Chronic Kidney Disease in Type 2 Diabetes Chronic kidney disease (CKD) is a common and potentially deadly condition that is widely underrecognized. ...
ByBayer AG
(NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced that it will be carrying out an NIH-sponsored Phase I study of Bioflux-AI, Biotricity’s innovative artificial intelligence-driven (‘AI’) system of real-time monitoring and prediction technology, in subjects with ...
About Chronic Kidney Disease in Type 2 Diabetes Chronic kidney disease (CKD) is a common and potentially deadly condition that is widely underrecognized. ...
ByBayer AG
Conn Hastings, Medgadget: Please explain the importance of regular cardiac monitoring in enabling early interventions and reducing disease exacerbation. John Lipman, Bodyport: Regular cardiac monitoring enables early interventions that lead to a reduction in disease exacerbation through timely and enhanced care. ...
“We are proud soon to be able to offer physicians a new, disease-modifying intervention improving patients’ outcomes, by delaying their chronic kidney disease ...
ByBayer AG
The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in ...
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients First launches in Europe expected in H2 2022 Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. ...
These figures are increasing due to rising incidence of chronic kidney disease, diabetes and acute kidney injury. Haemodialysis and Peritoneal Dialysis are the two main treatment methods used today. ...
The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in ...
(Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced biomarker data from the KALM-1 and KALM-2 clinical trials evaluating KORSUVA™ (difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus ...
“There is a high burden of type 2 diabetes in Japan, and a large proportion of people with type 2 diabetes develop chronic kidney disease. Despite well-controlled blood glucose levels and blood pressure, patients with chronic kidney disease and type 2 diabetes remain at risk of ...
ByBayer AG
The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in ...
If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval of VX-147 in the U.S. for patients with AMKD. About APOL1-Mediated Kidney Disease APOL1-mediated kidney disease is a form of chronic kidney disease caused by mutations in the APOL1 ...
Oral presentation will include biomarker data from KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients Oral KORSUVA (difelikefalin) Phase 3 pruritus programs in non-dialysis dependent advanced chronic kidney disease and atopic dermatitis, respectively, ...
The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in ...
If approved, Kapruvia® will be the first therapy available in Europe for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis patients. ...